Amino acid metabolism in liver disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 2, Issue 1, 1999, Pages 47-53

  Holm, Eggert ^a,b   Sedlaczek, Oliver ^a   Grips, Eva ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Theodor Kutzer Ufer   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMMONIA; BRANCHED CHAIN AMINO ACID; METHIONINE; NERVE GROWTH FACTOR; TRYPTOPHAN; UREA;

ANIMAL; BLOOD; HUMAN; LIVER DISEASE; METABOLISM; REVIEW;

AMINO ACIDS; AMINO ACIDS, BRANCHED-CHAIN; AMMONIA; ANIMALS; HUMANS; LIVER DISEASES; METHIONINE; NERVE GROWTH FACTORS; TRYPTOPHAN; UREA;

EID: 0032602133     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-199901000-00009     Document Type: Article

References (80)

1. 13C] Phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. Am J Surg 1997; 173:270-274. An oral phenylalanine breath test is proposed as a method for quantifying the functional reserve of the liver.
2. Marchesini G, Bugianesi E, Bianchi G, Fabbri A, Marchi E, Zoli M, Pisi E. Defective methionine metabolism in cirrhosis: relation to severity of liver disease. Hepatology 1992; 16:149-155.
3. Rössle M, Herz R, Klein B, Gerok W. Tryptophan-Metabolismus bei Lebererkrankungen: eine pharmakokinetische und enzymatische Untersuchung. Klin Wochenschr 1986; 64:590-594.
4. Leweling H, Staedt U, Striebel JP, Holm E. Hepatic failure: nutritional measures and treatment of encephalopathy. SA J Clin Nutr 1988; 1:11-30.
5. Stahl J. Studies of the blood ammonia in liver disease. Its diagnostic, prognostic, and therapeutic significance. Ann Int Med 1963; 58:1-24.
6. Kitani T. Coma hepaticum. Proc Int Congr Gastroenterol 1960; 30:465-482.
7. Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy RGB, Rudman D. Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology 1984; 87:770-776.
8. Bianchi G, Bugianesi E, Ronchi M, Fabbri A, Zoli M, Marchesini G. Glutathione kinetics in normal man and in patients with liver cirrhosis. J Hepatol 1997; 26:606-613. An excellent analysis of glutathione kinetics. Measurements: clearance rate, half-life, volume of distribution, and endogenous basal appearance rate. The lowering of glutathione plasma levels in cirrhosis was confirmed and a reduced production was ascertained as the primary defect.
9. Horowitz JH, Rypins EB, Henderson JM, Heymsfield SB, Moffitt SD, Bain RP, et al. Evidence for impairment of transsulfuration pathway in cirrhosis. Gastroenterology 1981; 81:668-675.
10. Mato JM, Ortiz P. Metabolism of methionine in liver disease. Meth Find Exp Clin Pharmacol 1996; 18 (Suppl. B):35-46.
11. Avila MA, Carretero MV, Rodriguez EN, Mato JM. Regulation by hypoxia of methionine adenosyltransferase activity and gene expression in rat hepatocytes. Gastroenterology 1998; 114:364-371. An experimental study evaluating the influence of oxygen tension on MAT activity and expression. The results are clinically relevant.
12. Sánchez-Góngora E, Ruiz F, Mingorance J, An W, Corrales FJ, Mato JM. Interaction of liver methionine adenosyltransferase with hydroxyl radical. FASEB J 1997; 11:1013-1019. An in-vttro and in-vivo demonstration that hydrogen peroxide, via generation of the hydroxyl radical, inactivates liver MAT by reversibly and covalently oxidizing an enzyme site. Cysteine 121 was identified as the enzyme site where the oxidative modification occurs.
13. Shattuck KE, Rassin DK, Grinnell CD. N-acetylcysteine protects from glutathione depletion in rats exposed to hyperoxia. J Parenter Enter Nutr 1998; 22:228-233. Experiments showing that N-acetylcysteine may prevent oxidant stress during hyperoxic exposure, probably by supplying cysteine as a precursor for glutathione synthesis.
14. Cao Y, Feng Z, Hoos A, Klimberg VS. Glutamine enhances gut glutathione production. J Parenter Enter Nutr 1998; 22:224-227. A demonstration in rats that glutathione production by the gut should not be neglected and can be enhanced by supplemental oral glutamine.
15. Fürst P, Pogan K, Stehle P. Glutamine dipeptides in clinical nutrition. Nutrition 1997; 13:731-737.
16. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1:228-237.
17. Marchesini G, Bugianesi E, Bianchi G, Fabbri A, Marchi E, Zoli M, Pisi E. Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. Clin Nutr 1992; 11:303-308.
18. Gassó M, Rubio M, Varela G, Cabré M, Caballería J, Alonso E, et al. Effects of S-adenosyl-methionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. J Hepatol 1996; 25:200-205.
19. Mato JM, Cámara J, Ortiz P, Rodés J, and Spanish Collaborative Group for the Study of Alcoholic Liver Cirrhosis Madrid. S-adenosylmethionine in the treatment of alcoholic liver cirrhosis. Results from a multicentric, placebo-controlled, randomized, double-blind clinical trial. Hepatology 1997; 26:251A.
20. Bugianesi E, Tangerman A, Ronchi M, Bianchi G, Marchesini G. Transamination of methionine after loading in patients with cirrhosis. J Hepatol 1996; 24:95-100.
21. Zieve L, Doizaki WM, Zieve FJ. Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 1974; 83:16-28.
22. Holm E, Jacob S, Kortsik C, Leweling H, Fischer B. Failure of selective serotonin re-uptake inhibition to worsen the mental state of patients with subclinical hepatic encephalopathy. In: Advances in ammonia metabolism and hepatic encephalopathy. Soeters PB, Wilson JHP, Meijer AJ, Holm E (editors). International Congress Series 761; Amsterdam: Elsevier; 1988. pp. 474-486.
23. Laviano A, Cangiano C, Preziosa I, Riggio O, Conversano L, Cascino A, et al. Plasma tryptophan levels and anorexia in liver cirrhosis. Int J Eat Disord 1997; 21:181-186. This paper offers interesting findings that may prompt further pharmacological investigations in the field of anorexia.
24. Bengtsson F, Bergqvist P. Neuropsychiatric implications of brain tryptophan perturbations appearing in hepatic encephalopathy. Adv Exp Med Biol 1996; 398:387-395.
25. Colombo JP, Bachmann C, Cervantes H, Kokorovic M, Perritaz R. Tyrosine uptake and regional brain monoamine metabolites in a rat model resembling congenital hyperammonemia. Pediatr Res 1996; 39:1036-1040.
26. James JH, Ziparo V, Jeppsson B, Fischer JE. Hyperammonemia, plasma amino acid imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic encephalopathy. Lancet 1979; ii:772-775.
27. Cangiano C, Cardelli-Gangiano P, James JH, Rossi-Fanelli F, Patrizi MA, Brackett KA, et al. Brain microvessels take up large neutral amino acids in exchange for glutamine. J Biol Chem 1983; 258:8949-8954.
28. Bergqvist PBF, Some M, Apelqvist G, Helander A, Bengtsson F. Elevated brain 5-hydroxytryptophol levels in experimental portal-systemic encephalopathy. Pharmacol Toxicol 1997; 80:187-190. Presents a novel potential pathogenetic factor in HE.
29. Bergqvist PBF, Vogels BAPM, Bosman DK, Maas MAW, Hjorth S, Chamuleau RAFM, Bengtsson F. Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt. J Neurochem 1995; 64:1238-1244.
30. Bergqvist PBF, Hjorth S, Apelqvist G, Bengtsson F. Acute effects of L-tryptophan on brain extracellular 5-HT and 5-HIAA levels in chronic experimental portal-systemic encephalopathy. Metab Brain Dis 1996; 11:269-278.
31. Bergqvist PBF, Hjorth S, Audet RM, Apelqvist G, Bengtsson F, Butterworth RF. Ammonium acetate challenge in experimental chronic hepatic encephalopathy induces a transient increase of brain 5-HT release in vivo. Eur Neuropsychopharmacol 1996; 6:317-322.
32. Bergqvist PBF, Hjorth S, Apelqvist G, Bengtsson F. Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy. Metab Brain Dis 1997; 12:193-202. A carefully designed investigation with convincing results, which, however, were obtained under somewhat artificial experimental conditions.
33. Bergqvist PBF, Heyes MP, Apelqvist G, Butterworth RF, Bengtsson F. Brain extracellular quinolinic acid in chronic experimental hepatic encephalopathy as assessed by in vivo microdialysis: acute effects of L-tryptophan. Neuropsychopharmacology 1996; 15:382-389.
34. Holm E, Möller M, Viell B, Pohlmann-Eden B, Leweling H, Schlüter M, Tokus M. Kynurenine, non-transmitter indoles and encephalopathy in patients with liver cirrhosis. In: Advances in hepatic encephalopathy and metabolic nitrogen exchange. Capocaccia L, Merli M, Riggio O (editors). Boca Raton: CRP Press; 1995. pp. 205-227.
35. Moroni F, Lombardi G, Carla V, Lal S, Etienne P, Nair NP. Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure. J Neurochem 1986; 47:1667-1671.
36. Jessy J, Mans AM, DeJoseph MR, Hawkins RA. Hyperammonaemia causes many of the changes found after portacaval shunting. Biochem J 1990; 272:311-317.
37. Karavias T. Der Einfluss zweier hämodynamisch unterschiedlicher portosystemischer Anastomosen auf die hepatischen und zerebralen Funktionen der gesunden und zirrhotischen Ratte. Berlin: Med. Habilitationsschrift; 1983.
38. Holm E, Leweling H, Staedt U, Striebel JP, Tschepe A, Uhl W. Protein-und Aminosäurenstoffwechesl bei Leberinsuffizienz-Infusionstherapeutische und diätetische Folgerungen. Verh Dtsch Ges Inn Med 1986; 92:685-737.
39. Datta DV, Agarwalla ML, Narang APS, Samanta AKS, Chhuttani PN. Ammonia tolerance test in liver disease with special reference to non-cirrhotic portal fibrosis. Indian J Med Res 1979; 70:825-832.
40. Holm E, Behne F, Leweling H, Staedt U, Striebel JP, Tschepe A. Animal models of hepatic failure. Metabolic characteristics and effects of TPN. In: Clinical nutrition and metabolic research. Dietze G, Grünert A, Kleinberger G, Wolfram G (editors). Basel: Karger; 1986. pp. 343-374.
41. Sarin SK, Nundy S. Subclinical encephalopathy after portosystemic shunts in patients with non-cirrhotic portal fibrosis. Liver 1985; 5:142-148.
42. Holm E, Striebel JP, Kattermann R, Schick E, Staedt U. Encephalopathy resulting from portacaval anastomosis in cats. Ammonia, amino acids, and cerebral electrical activity. In: Amino acid and ammonia metabolism in hepatic failure. Holm E (editor). Baden-Baden: Witzstrock; 1982. pp. 58-94.
43. Bengtsson F, Nobin A, Falck B, Gage FH, Jeppsson B. Portacaval shunt in the rat: selective alterations in behavior and brain serotonin. Pharmacol Biochem Behav 1986; 24:1611-1616.
44. Mullen KD, Roessle M, Jones DB, Grun M, Jones EA. Precipitation of overt encephalopathy in the portacaval shunted rat: towards the development of an adequate model of chronic portal systemic encephalopathy. Eur J Gastroenterol Hepatol 1997; 9:293-298. This publication should receive the widest possible attention. Although not including amino acid data, it creates the relevant background against which hyperammonaemia-associated changes in amino acid metabolism should be viewed. The induction of overt encephalopathy in portacaval shunted rats necessitated additional procedures such as an impairment of liver function and blood gavaging. The difference between PSE and HE is not specifically addressed but is implicit in the paper. Experimental models of acute-on-chronic PSE/HE are described.
45. Hindfelt B, Plum F, Duffy TE. Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest 1977; 59:386-396.
46. Holm E (editor). Ammoniak und hepatische Enzephalopathie, Biochemie, Elektrophysiologie, Toxikologie. Stuttgart: Fischer; 1975.
47. Tokus M, Böhles H, Schadewaldt P, Viell B, Holm E. Metabolische Parameter bei fulminantem Leberversagen (FLV). Kasuistik einer Patientin mit M. Wilson. Akt Ern Med 1998; 23:91-92.
48. Lockwood AH, Yap EWH, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11:337-341.
49. Dejong CHC, Deutz NEP, Soeters PB. Ammonia and glutamine metabolism during liver insufficiency: the role of kidney and brain in interorgan nitrogen exchange. Scand J Gastroenterol 1996; 31 (Suppl. 218):61-77.
50. Huizenga JR, Gips CH, Tangerman A. The contribution of various organs to ammonia formation: a review of factors determining the arterial ammonia concentration. Ann Clin Biochem 1996; 33:23-30.
51. Häussinger D, Laubenberger J, vom Dahl S, Ernst T, Bayer S, Langer M, et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 1994; 107:1475-1480.
52. Cordoba J, Gottstein J, Blei AT. Glutamine, myo-inositol, and organic brain osmolytes after portacaval anastomosis in the rat: implications for ammonia induced-brain edema. Hepatology 1996; 24:919-923.
53. Laubenberger J, Hässinger D, Bayer S, Gufler H, Hennig J, Langer M. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997; 112:1610-1616. An informative description of glutamine accumulation and myoinositol depletion in the brains of patients with liver cirrhosis, where these metabolic changes occur already in the absence of subclinical encephalopathy. The question of whether in severe clinical HE the marked further increase in brain glutamine may contribute to the pathogenesis, can not be answered on the basis of this study. Information about conventional biochemical data of the patients would have been desirable.
54. Greulich G, Leweling H, Fiedler G, Tokus M, Weber T, Holm E. Beziehungen zwischen konventionellen blutchemischen Parametern, Plasmaaminosäuren, Kynurenin, freien Fettsäuren und hepatischer Enzephalopathie (HE) bei Leberzirrhose - eine Hauptkomponentenanalyse [Abstract]. Akt Ern Med 1996; 21:58.
55. Mullen KD, Gacad R, Kaminsky-Russ K. Reducing brain glutamine synthesis does not improve behavior in portacaval shunted rats. In: Advances in hepatic encephalopathy and metabolism in liver disease. Record C, Al-Mardini H (editors). Newcastle upon Tyne: Medical Faculty, University of Newcastle; 1997. pp. 423-426. Preliminary communication casting doubt on a pathogenetic role of increased brain glutamine synthesis for the behavioural abnormalities occurring in animals with PCA.
56. Raabe W, Onstad G. Porta-caval shunting changes neuronal sensitivity to ammonia. J Neurol Sci 1985; 71:307-314.
57. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmüller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with liver cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 1993; 19:424-430.
58. Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF. Ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 1998; 13:147-157. Experiments on the protective effectiveness of ornithine aspartate in portacaval shunted rats subjected to an acute ammonia load. Coma was prevented despite a significant rise in cerebrospinal glutamine concentration.
59. Butterworth RF. Neuroactive amino acids in hepatic encephalopathy. Metab Brain Dis 1996; 11:165-173.
60. Olde Damink SWM, Dejong CHC, Deutz NEP, Soeters PB. Effects of simulated upper gastrointestinal hemorrhage on ammonia and related amino acids in blood and brain of chronic portacaval-shunted rats. Metab Brain Dis 1997; 12:121-135. A clinically relevant, experimental study focused on cerebral cortex glutamate content after intragastric blood administration in PCA rats. The blood gavages induced a deterioration of the neurological state without altering brain glutamate concentration. In addition to ammonia and glutamine, substances such as GABA, phenylalanine and tyrosine were markedly increased in brain tissue, whereas taurine was decreased. The authors suggest that future research should concentrate on releasable neurotransmitter pools.
61. Yudkoff M. Brain metabolism of branched-chain amino acids. Glia 1997; 21:92-98. An excellent review on brain metabolism of ammonia-related amino acids, with emphasis on the BCAA. Convincing evidence is put forward for the existence of a 'leucine-glutamate cycle' which may 'buffer' brain glutamate if the concentration of this neurotransmitter becomes elevated.
62. Butterworth J, Gregory CR, Aronson LR. Selective alterations of cerebrospinal fluid amino acids in dogs with congenital portosystemic shunts. Metab Brain Dis 1997; 12:299-305. The pathogenesis of HE in dogs with congenital PSS is generally thought to be largely analogous to that of HE in human cirrhosis, because in these animals PSS is associated with distinct liver insufficiency. Increased amounts of glutamine, glutamate, and aromatic amino acids were found in the cerebrospinal fluid.
63. Soeters PB, de Boer JEG. Why are plasma branched-chain amino acid levels diminished in patients with liver cirrhosis? In: Branched-chain amino and keto-acids in health and disease. Adibi SA, Fekl W, Langenbeck U, Schauder P (editors). Basel: Karger; 1984. pp. 483-496.
64. Petrides AS. Regulation by insulin of branched chain amino acid metabolism in cirrhosis. Ital J Gastroenterol 1993; 25:144-150.
65. Iwasaki Y, Sato H, Ohkubo A, Sanjo T, Futagawa S, Sugiura M, Tsuji S. Effect of spontaneous portal-systemic shunting on plasma insulin and amino acid concentrations. Gastroenterology 1980; 78:677-683.
66. Ouchi K, Matsubara S, Fukuhara K, Matsuno S. Plasma amino acid abnormalities in liver disease: comparative analysis of idiopathic portal hypertension, extrahepatic portal occlusion and liver cirrhosis. Tohoku J Exp Med 1989; 158:171-178.
67. Strombeck DR, Rogers Q, Stern JS. Effects of intravenous ammonia infusion on plasma levels of amino acids, glucagon and insulin in dogs. Gastroenterology 1978; 74:1165.
68. Record C, Buxton B, Chase RA, Curzon G, Murray-Lyon IM, Williams R. Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy. Eur J Clin Invest 1976; 6:387-394.
69. Leweling H, Breitkreutz R, Behne F, Staedt U, Striebel JP, Holm E. Hyperammonemia-induced depletion of glutamate and branched-chain amino acids in muscle and plasma. J Hepatol 1996; 25:756-762.
70. Hayashi M, Ohnishi H, Kawade Y, Muto Y, Takahashi Y. Augmented utilization of branched-chain amino acids by skeletal muscle in decompensated liver cirrhosis in special relation to ammonia detoxication. Gastroenterol Jap 1981; 16:64-70.
71. 15N in the amido group of glutamine seems somewhat speculative.
72. Yamato M, Muto Y, Yoshida T, Kato M, Moriwaki H. Clearance rate of plasma branched-chain amino acids correlates significantly with blood ammonia level in patients with liver cirrhosis. Int Hepatol Commun 1995; 3:91-96.
73. Campollo O, Sprengers D, McIntyre N. The BCAA/AAA ratio of plasma amino acids in three different groups of cirrhotics. Rev Inv Clin 1992; 44:513-518.
74. Tesdal KI, Müller C, Kasper S, Filser T, Tokus M, Jentschura D, Holm E. Metabolic changes induced in cirrhotic patients by shunting procedures: a comparison between the transjugular intrahepatic portosystemic shunt (TIPS) and the portacaval end-to-side-shunt (PCS). In: Advances in hepatic encephalopathy and metabolism in liver disease. Record C, Al-Mardini H (editors). Newcastle upon Tyne: Medical Faculty, University of Newcastle; 1997. pp. 69-79.
75. Holecek M, Tilser I, Skopec F, Sprongl L. Leucine metabolism in rats with cirrhosis. J Hepatol 1996; 24:209-216.
76. Vilstrup H. Synthesis of urea after stimulation with amino acids: relation to liver function. Gut 1980; 21:990-995.
77. Hamberg O. Regulation of urea synthesis by diet protein and carbohydrate in normal man and in patients with cirrhosis. Relationship to glucagon and insulin. Dan Med Bull 1997; 44:225-241. This is an outstanding, detailed review describing the regulation of urea synthesis rate by both nutrient intake and hormones. Results of the experiments are discussed together with data taken from the literature. The implications for whole-body nitrogen economy are fully outlined.
78. Droge W, Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. FASEB J 1997; 11:1077-1089.
79. 1 improved amino acid-nitrogen economy. A decrease in plasma amino acids and in urea-nitrogen synthesis rate as well as a positive total body nitrogen exchange were observed, with at least one of the underlying mechanisms probably being operative at the peripheral level (reduced amino acid flux to the liver).
80. Gebhardt R, Beckers G, Gaunitz F, Haupt W, Jonitza D, Klein S, Scheja L. Treatment of cirrhotic rats with L-omithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels. J Pharmacol Exp Ther 1997; 283:1-6. This study shows that ornithine aspartate, although enhancing urea formation, may beneficially influence nitrogen metabolism by promoting protein synthesis. Both of these effects are likely to contribute to the ornithine aspartate-induced reduction in the plasma ammonia level.